Kymera Therapeutics Inc Ordinary Shares KYMR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $134.84
- Day Range
- $128.10–134.45
- 52-Week Range
- $62.33–142.46
- Bid/Ask
- $128.88 / $129.49
- Shares Outstanding
- 85.37M
- Market Cap
- $11.00B
- Volume/Avg
- 295,340 / 827,839
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 127.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 285
- Website
- https://www.kymeratx.com
Valuation
Metric | KYMR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.13 |
Price/Sales | 127.22 |
Price/Cash Flow | — |
Price/Earnings
KYMR
Financial Strength
Metric | KYMR |
|---|---|
Quick Ratio | 10.82 |
Current Ratio | 11.13 |
Interest Coverage | −1,381.88 |
Quick Ratio
KYMR
Profitability
Metric | KYMR |
|---|---|
Return on Assets (Normalized) | −17.74% |
Return on Equity (Normalized) | −19.56% |
Return on Invested Capital (Normalized) | −22.17% |
Return on Assets
KYMR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|^F^jPCG | LOCK|&#kh! | $139B | |||
| Moderna Inc MRNA | LOCK|%x%!f&# | LOCK|%^ | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<G#NbyR | LOCK|@F%Vn | $99B | |||
| argenx SE ADR ARGX | LOCK|>^!f>^ | LOCK|ly | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@M<hVjm | LOCK|@? | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|B!Y^vBCm | LOCK|rDvp | $31B | |||
| Incyte Corp INCY | LOCK|M$?z^%w | LOCK|<t | $25B | |||
| BioNTech SE ADR BNTX | LOCK|PgmF@@ | LOCK|!g@ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^w$!B? | LOCK|<<v$< | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Qdc%tD | LOCK|s# | $16B |
United States